{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T03:40:00Z","timestamp":1768707600819,"version":"3.49.0"},"reference-count":35,"publisher":"Japanese Society of Internal Medicine","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2025,5,1]]},"DOI":"10.2169\/internalmedicine.4337-24","type":"journal-article","created":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T22:10:53Z","timestamp":1726611053000},"page":"1296-1302","source":"Crossref","is-referenced-by-count":3,"title":["Pemafibrate Reduced Liver Stiffness in Patients with Metabolic Dysfunction-associated Steatotic Liver Disease Complicated with Hyperlipidemia and Liver Fibrosis with a Fibrosis-4 Index Above 1.3"],"prefix":"10.2169","volume":"64","author":[{"given":"Tatsuki","family":"Ichikawa","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Nagasaki Harbor Medical Center, Japan"},{"name":"Department of Comprehensive Community Care Systems, Graduate School of Biomedical Sciences, Nagasaki University, Japan"},{"name":"Innovation and Translational Research Center, Nagasaki Harbor Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mio","family":"Yamashima","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Nagasaki Harbor Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinobu","family":"Yamamichi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Nagasaki Harbor Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makiko","family":"Koike","sequence":"additional","affiliation":[{"name":"Innovation and Translational Research Center, Nagasaki Harbor Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Nakano","sequence":"additional","affiliation":[{"name":"Innovation and Translational Research Center, Nagasaki Harbor Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Yajima","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Nagasaki Harbor Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osamu","family":"Miyazaki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Nagasaki Harbor Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomonari","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Nagasaki Harbor Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuma","family":"Okamura","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Nagasaki Harbor Medical Center, Japan"},{"name":"Department of Comprehensive Community Care Systems, Graduate School of Biomedical Sciences, Nagasaki University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naohiro","family":"Komatsu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Nagasaki Harbor Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sayuri","family":"Sugio","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Nagasaki Harbor Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miruki","family":"Yoshino","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Nagasaki Harbor Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisamitsu","family":"Miyaaki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Graduate School of Biomedical Sciences, Nagasaki University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Paik JM, Henry L, Younossi Y, Ong J, Alqahtani S, Younossi ZM. The burden of nonalcoholic fatty liver disease (NAFLD) is rapidly growing in every region of the world from 1990 to 2019. Hepatol Commun 7: 2023.","DOI":"10.1097\/HC9.0000000000000251"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Huang DQ, Terrault NA, Tacke F, Gluud LL, Arrese M, Bugianesi E. Global epidemiology of cirrhosis - aetiology, trends and predictions. Nat Rev Gastroenterol Hepatol 2023.","DOI":"10.1038\/s41575-023-00759-2"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Shah PA, Patil R, Harrison SA. NAFLD-related hepatocellular carcinoma: the growing challenge. Hepatology 2022.","DOI":"10.1002\/hep.32542"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Ratziu V, Charlton M. Rational combination therapy for NASH: insights from clinical trials and error. J Hepatol 78: 1073-1079, 2023.","DOI":"10.1016\/j.jhep.2022.12.025"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol 73: 202-209, 2020.","DOI":"10.1016\/j.jhep.2020.07.045"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Kawaguchi T, Tsutsumi T, Nakano D, Eslam M, George J, Torimura T. MAFLD enhances clinical practice for liver disease in the Asia-Pacific region. Clin Mol Hepatol 28: 150-163, 2022.","DOI":"10.3350\/cmh.2021.0310"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Kawaguchi T, Tsutsumi T, Nakano D, Torimura T. MAFLD: renovation of clinical practice and disease awareness of fatty liver. Hepatol Res 52: 422-432, 2022.","DOI":"10.1111\/hepr.13706"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Rinella ME, Lazarus JV., Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol 79: 1542-1556, 2023.","DOI":"10.1097\/HEP.0000000000000696"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Nakano M, Kawaguchi M, Kawaguchi T. Almost identical values of various non-invasive indexes for hepatic \ufb01brosis and steatosis between NAFLD and MASLD in Asia. J Hepatol 80: e155-e157, 2024.","DOI":"10.1016\/j.jhep.2023.12.030"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Suzuki H, Tsutsumi T, Kawaguchi M, Amano K, Kawaguchi T. Changing from NAFLD to MASLD: prevalence and progression of ASCVD risk are similar between NAFLD and MASLD in Asia. Clin Mol Hepatol 577-579, 2024.","DOI":"10.3350\/cmh.2024.0157"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Nakano M, Kawaguchi M, Kawaguchi T, Yoshiji H. Profiles associated with significant hepatic fibrosis consisting of alanine aminotransferase >30 U\/L, exercise habits, and metabolic dysfunction-associated steatotic liver disease. Hepatol Res 56: 570-579, 2024.","DOI":"10.1111\/hepr.14020"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Harrison SA, Bedossa P, Guy CD, et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med 390: 497-509, 2024.","DOI":"10.1056\/NEJMoa2309000"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. The Lancet Gastroenterology & Hepatology. Resmetirom for NASH: balancing promise and prudence. Lancet Gastroenterol Hepatol 9: 273, 2024.","DOI":"10.1016\/S2468-1253(24)00049-9"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Ishibashi S, Arai H, Yokote K, Araki E, Suganami H, Yamashita S. Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor \u03b1 modulator, in patients with dyslipidemia: results from a 24-week, randomized, double blind, active-controlled, phase 3 trial. J Clin Lipidol 12: 173-184, 2018.","DOI":"10.1016\/j.jacl.2017.10.006"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Nakajima A, Eguchi Y, Yoneda M, et al. Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator-activated receptor \u03b1 modulator (SPPARM\u03b1), versus placebo in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 54: 1263-1277, 2021.","DOI":"10.1111\/apt.16596"},{"key":"16","unstructured":"16. Das Pradhan A, Glynn RJ, Fruchart J-C, et al. Triglyceride lowering with pemafibrate to reduce cardiovascular risk. N Engl J Med 387: 1923-1934, 2022."},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Sugimoto R, Iwasa M, Eguchi A, et al. Effect of pemafibrate on liver enzymes and shear wave velocity in non-alcoholic fatty liver disease patients. Front Med (Lausanne) 10: 2023.","DOI":"10.3389\/fmed.2023.1073025"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Takahashi Y, Seko Y, Yamaguchi K, et al. Gamma-glutamyl transferase predicts pemafibrate treatment response in non-alcoholic fatty liver disease. J Gastroenterol Hepatol (Australia) 38: 1743-1749, 2023.","DOI":"10.1111\/jgh.16222"},{"key":"19","doi-asserted-by":"publisher","unstructured":"19. Ichikawa T, Oba H, Owada M, et al. Evaluation of the effects of pemafibrate on metabolic dysfunction-associated steatotic liver disease with hypertriglyceridemia using magnetic resonance elastography combined with fibrosis-4 index and the magnetic resonance imaging-aspartate aminotransferase score. JGH Open 7: 959-965, 2023.","DOI":"10.1002\/jgh3.13012"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Morishita A, Oura K, Takuma K, et al. Pemafibrate improves liver dysfunction and non-invasive surrogates for liver fibrosis in patients with non-alcoholic fatty liver disease with hypertriglyceridemia: a multicenter study. Hepatol Int 17: 606-614, 2023.","DOI":"10.1007\/s12072-022-10453-1"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Ono H, Atsukawa M, Tsubota A, et al. Impact of pemafibrate in patients with metabolic dysfunction-associated steatotic liver disease complicated by dyslipidemia: A single-arm prospective study. JGH Open 8: 2024.","DOI":"10.1002\/jgh3.13057"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Ishikawa T, Terai N, Igarashi T, et al. Effects of body composition and liver function after long-term pemafibrate treatment on dyslipidemiaassociated non-alcoholic fatty liver disease. Clin Exp Hepatol 9: 172-178, 2023.","DOI":"10.5114\/ceh.2023.127813"},{"key":"23","unstructured":"23. Shephard DA. The 1975 Declaration of Helsinki and consent. Can Med Assoc J 115: 1191-1192, 1976."},{"key":"24","doi-asserted-by":"publisher","unstructured":"24. Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and FibroTest. Hepatology 46: 32-36, 2007.","DOI":"10.1002\/hep.21669"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Ng CH, Lim WH, Chin YH, et al. Living in the nonalcoholic fatty liver disease (NAFLD) silent epidemic. A systematic review of patients' perspectives. Aliment Pharmacol Ther 54: 655-666, 2022.","DOI":"10.2139\/ssrn.4059221"},{"key":"26","doi-asserted-by":"publisher","unstructured":"26. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty. Hepatology 77: 1797-1835, 2023.","DOI":"10.1097\/HEP.0000000000000323"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Yamaguchi M, Asano T, Arisaka T, Mashima H, Irisawa A, Tamano M. Effects of pemafibrate on primary biliary cholangitis with dyslipidemia. Hepatol Res 52: 522-531, 2022.","DOI":"10.1111\/hepr.13747"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Tamai H, Okamura J. Safety and efficacy of switching to pemafibrate from bezafibrate in patients with chronic liver disease. Hepatol Res 53: 258-266, 2023.","DOI":"10.1111\/hepr.13859"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Suzuki Y, Maekawa S, Yamashita K, et al. Effect of a combination of pemafibrate and a mild low-carbohydrate diet on obese and non-obese patients with metabolic-associated fatty liver disease. J Gastroenterol Hepatol (Australia) 38: 921-929, 2023.","DOI":"10.1111\/jgh.16154"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Lefere S, Puengel T, Hundertmark J, et al. Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages. J Hepatol 73: 757-770, 2020.","DOI":"10.1016\/j.jhep.2020.04.025"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Nikam A, Patankar JV., Somlapura M, et al. The PPAR\u03b1 agonist fenofibrate prevents formation of protein aggregates (mallory-denk bodies) in a murine model of steatohepatitis-like hepatotoxicity. Sci Rep 8: 2018.","DOI":"10.1038\/s41598-018-31389-3"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Honda Y, Kessoku T, Ogawa Y, et al. Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis. Sci Rep 7: 2017.","DOI":"10.1038\/srep42477"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Vilar-Gomez E, Vuppalanchi R, Gawrieh S, Samala N, Chalasani N. CAP and LSM as determined by VCTE are independent predictors of all-cause mortality in the US adult population. Hepatology 77: 1241-1252, 2023.","DOI":"10.1097\/HEP.0000000000000023"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Lee HW, Kim KH, Ahn SH, Lee HC, Choi J. The associations between fibrosis changes and liver-related events in patients with metabolic dysfunction-associated steatotic liver disease. Liver Int 44 (6): 2024.","DOI":"10.1111\/liv.15897"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Noureddin N, Noureddin M, Singh A, Alkhouri N. Progression of nonalcoholic fatty liver disease-associated fibrosis in a large cohort of patients with type 2 diabetes. Dig Dis Sci 67: 1379-1388, 2022.","DOI":"10.1007\/s10620-021-06955-x"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/9\/64_4337-24\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T04:01:21Z","timestamp":1746244881000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/9\/64_4337-24\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,1]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.4337-24","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,1]]},"article-number":"4337-24"}}